Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

嵌合抗原受体 汽车T细胞治疗 免疫学 抗体 B细胞 医学 免疫 抗体疗法 抗原 T细胞 病毒学 免疫系统 单克隆抗体
作者
Carla Simone Walti,Elizabeth M. Krantz,Joyce Maalouf,Jim B. Boonyaratanakornkit,Jacob Keane-Candib,Laurel Joncas-Schronce,Terry Stevens‐Ayers,Sayan Dasgupta,Justin J. Taylor,Alexandre V. Vinaud Hirayama,Merav Bar,Rebecca Gardner,Andrew J. Cowan,Damian J. Green,Michael J. Boeckh,David G. Maloney,Cameron John Turtle,Joshua Aiden Hill
出处
期刊:JCI insight [American Society for Clinical Investigation]
卷期号:6 (11) 被引量:100
标识
DOI:10.1172/jci.insight.146743
摘要

BACKGROUNDLittle is known about pathogen-specific humoral immunity after chimeric antigen receptor-modified T (CAR-T) cell therapy for B cell malignancies.METHODSWe conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen-targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected ("epitope hits") using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections.RESULTSWe enrolled 65 children and adults a median of 20 months after CD19- (n = 54) or BCMA- (n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%-73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18-1.25) and had fewer pathogen-specific epitope hits (mean difference, -90 epitope hits; 95% CI, -157 to -22).CONCLUSIONSeroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies.FUNDINGSwiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阿白发布了新的文献求助10
刚刚
活力板凳完成签到,获得积分10
1秒前
在水一方的应助被XIYBO采纳,获得10
1秒前
我是老大的应助被寒冷鸭子采纳,获得10
1秒前
2秒前
甜美的尔柳完成签到,获得积分10
2秒前
2秒前
长风完成签到,获得积分10
2秒前
Ava的应助被xie采纳,获得10
3秒前
pandaheld完成签到,获得积分10
3秒前
Chelsea发布了新的文献求助20
4秒前
4秒前
4秒前
superchen完成签到,获得积分10
4秒前
科研通AI6.3的应助被爱笑丹云采纳,获得10
5秒前
斯文败类的应助被小杨采纳,获得10
5秒前
5秒前
hhh完成签到,获得积分10
6秒前
6秒前
爱科研的小民完成签到,获得积分10
6秒前
在望的应助被科小白采纳,获得10
6秒前
Owen的应助被务实的忆雪采纳,获得10
6秒前
风吹麦浪发布了新的文献求助10
7秒前
7秒前
风吹麦浪发布了新的文献求助10
7秒前
7秒前
wang5945发布了新的文献求助10
7秒前
8秒前
wwj完成签到,获得积分20
8秒前
howay发布了新的文献求助10
8秒前
9秒前
研友_VZG7GZ的应助被AKTAO采纳,获得10
9秒前
9秒前
小田儿完成签到 ,获得积分10
9秒前
cua完成签到,获得积分10
9秒前
10秒前
10秒前
zhang关注了科研通微信公众号
10秒前
丘比特的应助被啊啊啊啊采纳,获得10
10秒前
风吹麦浪发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519